Home > Insider Trading > Filing (0001193805-21-001014)

Filing Details

Accession Number:: 0001193805-21-001014
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-07-13 12:06:20
Reporting Period:: 2021-07-09

Accepted Time:: 2021-07-13 12:06:20
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1759425	Mirum Pharmaceuticals Inc.	MIRM	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1009258	Deerfield Management Company, L.p. (Series C)	345 Park Avenue South, 12Th Floor New York NY 10010	No	No	Yes	Yes
1010823	L.p. Mgmt Deerfield	345 Park Avenue South, 12Th Floor 37Th Floor New York NY 10010	No	No	Yes	Yes
1352546	E James Flynn	345 Park Avenue South, 12Th Floor New York NY 10010	No	No	Yes	Yes
1354395	Deerfield Special Situations Fund, L.p.	345 Park Avenue South, 12Th Floor 37Th Floor New York NY 10010	No	No	Yes	Yes
1646981	Deerfield Healthcare Innovations Fund, L.p.	345 Park Avenue South, 12Th Floor 37Th Floor New York NY 10010	No	No	Yes	Yes
1665736	Deerfield Mgmt Hif, L.p.	345 Park Avenue South, 12Th Floor 37Th Floor New York NY 10010	No	No	Yes	Yes
1680307	Deerfield Private Design Fund Iv, L.p.	345 Park Avenue South, 12Th Floor New York NY 10010	No	No	Yes	Yes
1713467	Deerfield Mgmt Iv, L.p.	345 Park Avenue South, 12Th Floor New York NY 10010	No	No	Yes	Yes

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-07-09	99,325	$15.81	0	No	4	S	Indirect	Through Deerfield Special Situations Fund, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	Through Deerfield Special Situations Fund, L.P.

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	1,558,456	Indirect	Through Deerfield Healthcare Innovations Fund, L.P.
Common Stock	1,724,456	Indirect	Through Deerfield Private Design Fund IV, L.P.

Footnotes

The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.81 to $15.91, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. ("Fund IV"). Deerfield Mgmt, L.P. is the general partner of Deerfield Special Situations Fund, L.P. ("Deerfield Special Situations"). Deerfield Mgmt HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. (collectively with Fund IV and Deerfield Special Situations, the "Funds"). Deerfield Management Company, L.P. is the investment manager of the Funds. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt HIF, L.P. and Deerfield Management Company, L.P.
In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.